BiomX (NYSEMKT: PHGE)
$0.76
(3.1%)
$0.02
Price as of January 10, 2025, 3:43 p.m. ET
BiomX Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BiomX Company Info
BiomX, Inc. operates as a clinical-stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer. The firm discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.